Evidence map›Paper›PMID 42187108›Full record

ArticleAmerican journal of hematology2026

Characteristics and Prognostic Implications in Newly Diagnosed KMT2Ar AML: A Multicenter Study of the ECLA Group.

Jiajia Pan, Chunmei Fu, Qing Ling, Ying Lu, Yifen Shi, Yunxiang Zhang, Shaoyuan Wang, Chunyan Ji, Shenxian Qian, Zhenqi Huang and 21 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Jiajia PanDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chunmei FuNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Qing LingDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ying LuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, China.ORCID https://orcid.org/0000-0003-2960-3131
Yifen ShiDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yunxiang ZhangShanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shaoyuan WangDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Chunyan JiDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.ORCID https://orcid.org/0000-0003-4438-1768
Shenxian QianDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, China.
Zhenqi HuangDepartment of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zheng GeDepartment of Hematology, Zhongda Hospital, School of Medicine, Southeast University, Institute of Hematology, Southeast University, Nanjing, China.
Jingcheng ZhangDepartment of Hematology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Guifang OuyangDepartment of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Chenghao JinJiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Quanyi LuDepartment of Hematology, Zhongshan Hospital of Xiamen University, Xiamen, China.
Li HuangDepartment of Hematology, The Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua, China.
Hongwei KongDepartment of Hematology, People's Hospital of Quzhou City, Quzhou, China.
Yu ZhuDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Zhiling YanDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.ORCID https://orcid.org/0009-0007-7856-2651
Debin LiuDepartment of Hematology, Quanzhou First Hospital, Fujian Medical University, Quanzhou, China.
Huawei JiangDepartment of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0001-9915-9668
Nianci ChenDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-2972-610X
Xiangjie LinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yile ZhouDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yi ZhangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xia LiDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hongyan TongDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0001-5603-4160
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID https://orcid.org/0000-0002-8166-9915
Suning ChenNational Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Huafeng WangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
East China Leukemia Alliance

Funding

Fundamental Research Funds for the Central Universities 226-2025-00186Key Research and Development Program of Zhejiang Province 2024C03162National Natural Science Foundation of China 82300170National Natural Science Foundation of China 82300174National Natural Science Foundation of China 82370162Zhejiang Provincial Nature Science Foundation of China LQ24H080007
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) harboring KMT2A rearrangement (KMT2Ar) was generally associated with poor prognosis. We enrolled 490 patients with KMT2Ar from the East China Leukemia Alliance between March 2013 and August 2025. KMT2A::MLLT3 was the most frequent KMT2Ar (31.6%), followed by KMT2A::MLLT4 (25.1%), KMT2A::ELL (20%), and KMT2A::MLLT10 (12.7%). KMT2A::MLLT4 showed an inferior prognosis. The most co-occurring gene mutations were KRAS (20.1%), NRAS (19.0%), TET2 (10.2%), WT1 (8.6%), and PTPN11 (7.4%). Trisomy 8 was more common in patients < 60 years, while FLT3-ITD was only detected in patients < 60 years. With a median follow-up time of 42.6 months, the median overall survival (OS) of all patients was 30.9 months, and the 3-year OS rate was 49.9%. Patients treated with venetoclax plus intensive chemotherapy (Ven+IC) showed the best composite complete remission (CRc) rate and OS compared to intensive chemotherapy, venetoclax plus reduced-intensive chemotherapy, and reduced-intensive chemotherapy (CRc rate: 89.5% vs. 62.4% vs. 57.3% vs. 61.4%; median OS: not reached vs. 39.9 months vs. 34.8 months vs. 12.7 months). Multivariate analysis identified multiparameter flow cytometry minimal residual disease negativity post-induction therapy, allogeneic hematopoietic stem cell transplantation, and Ven+IC as independent favorable prognostic factors for event-free survival (EFS), and KMT2A::MLLT4 fusion, EVI1 overexpression were independent unfavorable prognostic factors for EFS. In summary, our study showed characteristics and prognostic implications in newly diagnosed KMT2Ar AML in China.

Indexed as

Histone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinAdolescentAdultChinaFemaleGene RearrangementHumansMaleMiddle AgedMutationPrognosisSurvival RateYoung AdultHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID42187108
PMCPMC13331638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.